Therefore, MDSCs can exploit the adenosinergic pathway to suppress anti-tumor activity, as adenosine functionally inhibits CD4+ and CD8+ T-cells, and stimulates regulatory immune cells [50]. Here, CD8A is linked to neoplasm.